RxDoctor Payments Data

Peter Winkle

Gastroenterology · Cypress, CANPI 1992923460

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $3,628 of the $5,203 with a category attached, or 69.7%. 11 manufacturers reported payments, led by Mylan Specialty L.p. at 44.6% of the total. Reporting peaked in 2019 at $2,563 and has fallen 99.2% since, to $19 in 2024.

$5,203in general payments, 2019–2025

Across 51 payments — averaging $102.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mylan Specialty L.p.$2K
  • Pfizer$1K
  • Novo Nordisk AS$1K
  • AbbVie$286
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$177
  • Shionogi Inc$55
  • plus $77 from 5 others
$117,482,946in research payments, 2019–2025

Across 1,453 payments — averaging $80,855 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$22.1M
  • Bristol Myers Squibb$17.2M
  • E.r. Squibb & Sons, L.L.C.$17M
  • AbbVie$14.2M
  • Amgen$14.1M
  • Janssen Research & Development, LLC$6.9M
  • plus $26M from 29 others

What the payments were for

  • Travel & lodging$3,62870%
  • Food & beverage$1,55530%
  • Gifts$200%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,203 in reported general payments places this provider in the 65th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California

Other gastroenterology in Cypress

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →